Navigation Links
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
Date:5/23/2013

THURSDAY, May 23 (HealthDay News) -- Although a study in 2012 suggested a cancer drug could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now say they have been unable to duplicate those findings.

The teams said their research could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has serious side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash.

"Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects," said study co-author Robert Vassar, a professor of cell and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago. "This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene."

The U.S. Food and Drug Administration approved bexarotene in 1999 to treat refractory cutaneous T-cell lymphoma. Once approved, however, the drug also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to rapidly reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the initial study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the development of Alzheimer's.

Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the latest research, admitted being skeptical about the initial findings.

"We were surprised and excited -- even stunned -- when we first saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center news release. "The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too good to be true."

In attempting to duplicate the findings, the research teams found that they were indeed too good to be true.

"We all went back to our labs and tried to confirm these promising findings," Sisodia said. "We repeated the initial experiments -- a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper."

Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24 issue of the journal Science that they did not find any reduction in beta amyloid plaques during or after treatment with bexarotene in three different strains of mice.

Bexarotene has never been tested on people as a treatment for Alzheimer's disease. Currently, there is no cure or effective treatment for the progressive condition, which affects an estimated 5.3 million Americans.

More information

The U.S. National Institutes of Health provides more information on Alzheimer's disease.

-- Mary Elizabeth Dallas

SOURCE: University of Chicago Medical Center, news release, May 23, 2013.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
Breaking Medicine Technology: